Idarubicin versus Doxorubicin in Acute Myeloid Leukemia: A Parallel Randomized Trial with Pharmacoeconomic Analysis
Background: Acute Myeloid Leukemia (AML) is the most common form of acute leukemia among adults. Treatment of acute leukemia has been divided into induction chemotherapy and post-remission therapy. The goal of induction chemotherapy, that consists of anthracycline and cytarabine, is to achieve morph...
Main Authors: | Amany El Zeiny, Raafat Abdel-Fattah, Maggie Abbassie, Samar Farid |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2024-01-01
|
Series: | Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://ps.tbzmed.ac.ir/PDF/ps-30-135.pdf |
Similar Items
-
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
by: Prajwal Boddu, et al.
Published: (2018-09-01) -
The first attempt on fabrication of a nano-biosensing platform and exploiting first-order advantage from impedimetric data: Application to simultaneous biosensing of doxorubicin, daunorubicin and idarubicin
by: Shokoufeh Soleimani, et al.
Published: (2020-08-01) -
Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells
by: Petra Otevřelová, et al.
Published: (2021-01-01) -
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
by: Yunxin Zeng, et al.
Published: (2021-11-01) -
Idarubicin-bromelain combination sensitizes cancer cells to conventional chemotherapy
by: Abdullah Taşkın, et al.
Published: (2019-10-01)